• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Oxcarbazepine: Close, but no Cigar

Oxcarbazepine: Close, but no Cigar

March 9, 2020
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

You are selecting a mood stabilizer for a 29-year-old woman with mania. If it works, she’ll need to take it long term, but with adherence rates hovering around 50% in this illness, that’s not a likely prospect. The FDA-approved options are not very high on tolerability, but what about oxcarbazepine?

Oxcarbazepine (Trileptal) is often used in bipolar disorder in place of its FDA-approved cousin, carbamazepine (Equetro, Tegretol). The thinking is that oxcarbazepine is safer, better tolerated, and less prone to drug interactions. However, those assumptions don’t quite hold up to the facts, and there’s a pile of unpublished research that raises questions about whether oxcarbazepine even works.

Oxcarbazepine, carbamazepine: What’s the difference?
Oxcarbazepine and carbamazepine differ by only a single carbonyl bond, so it seems intuitive that they should have similar clinical effects. However, small differences like this can sometimes be profound. For example, imipramine and chlorpromazine differ only in two bonds, but the former is an antidepressant and the latter an antipsychotic. Oxcarbazepine and carbamazepine actually target different sodium channels, so there’s reason to doubt that they have overlapping clinical effects.

Does oxcarbazepine work?
Most experts say that oxcarbazepine does not treat bipolar disorder because it failed to work in two ­placebo-controlled trials. However, there are problems with those studies. The first was small (n = 55) and tested oxcarbazepine’s long-term preventative effects as an add-on to lithium. Lithium is very effective in the maintenance phase, so it may have washed out any benefits of the additional oxcarbazepine (Vieta E et al, Int J Neuropsychopharmacol 2008;11(4):445–452).

The second study evaluated oxcarbazepine’s acute antimanic effects in children and adolescents. It is the only large study of oxcarbazepine in bipolar disorder (n = 116), but only 62% of the subjects completed the study. To the drug’s credit, there were more dropouts in the placebo group, and oxcarbazepine outperformed placebo with a response rate of 42% vs 26%, but the better performance was not statistically significant (Wagner KD et al, Am J Psychiatry 2006;163(7):1179–1186).

Another flaw of the pediatric study is that it recruited from 20 research sites. Too many sites can cause studies to fail. When each site has only a handful of subjects, those subjects tend to get more attention, which enhances the placebo response. It’s also harder to keep the methods consistent across each site. The same authors conducted a similar multisite study of ­valproate in pediatric mania, and the active treatment failed to separate from placebo there as well.

Oxcarbazepine performed better when it was compared to other mood stabilizers instead of to a placebo. In nine studies involving 318 subjects, it worked as well as lithium, valproic acid, carbamazepine, and haloperidol in mania and mixed states (seven studies), hypomania (one study), or the maintenance phase (one study) (Vasudev A et al, Cochrane Database Syst Rev 2011;12:CD004857). The best results were achieved when oxcarbazepine was used to augment lithium in mania, where it actually outperformed carbamazepine.

The main limitation of these studies is that they were small and lacked a placebo control. Without a placebo, we don’t know if the improvements in both groups were due to nonspecific factors. Simply entering the structured setting of a controlled trial can improve manic symptoms.

Oxcarbazepine may have a role in specific symptoms. For example, it reduced impulsivity and aggression in small, placebo-controlled studies of patients with and without bipolar disorder (Mattes JA, J Clin Psychopharmacol 2005;25(6):575–579).
Table: How to Use Oxcarbazepine in Bipolar Disorder

Table: How to Use Oxcarbazepine in Bipolar Disorder

(Click to view full-size PDF.)

What about safety?
The hope of oxcarbazepine is that it’s close enough to carbamazepine to treat bipolar, but different enough to be safer and more tolerable. There’s a grain of truth to that.

Oxcarbazepine was about 20% less likely to cause side effects than carbamazepine in the studies that compared the two drugs, both in epilepsy and bipolar disorder. The side effects it did cause were similar to those seen with carbamazepine: headache, dizziness, somnolence, nausea, and rash. Side effects are most likely to occur in the first 4 weeks of treatment and tend to be transient.

In terms of safety, oxcarbazepine is better in some respects and worse in others. It has a higher risk of hyponatremia. The risk of severe hyponatremia (Na < 125) is 1.3% for oxcarbazepine vs 0.1% for carbamazepine; for mild, it’s 30% vs 15%. Severe hyponatremia can lead to seizures, coma, and death. Annual electrolyte checks will catch some cases of hyponatremia in the early stages but miss the majority, so warn patients of the signs: malaise, nausea, dizziness, and headache.

On the other hand, the aplastic anemia and agranulocytosis seen with carbamazepine (at a rate of 1 in 100,000) are not seen with oxcarbazepine. Both medications carry a risk of rash, Stevens-Johnson syndrome, and elevated liver enzymes. Patients of Asian descent should be screened for the HLA-B*1502 allele, as this confers an increased risk of severe skin reactions with both carbamazepine and oxcarbazepine.

Oxcarbazepine is also thought to lack the problematic drug interactions of carbamazepine. As a potent inducer at CYP3A4, carbamazepine renders many medications nearly ineffective, including antidepressants and antipsychotics. However, oxcarbazepine also induces CYP3A4 in the higher dose range that’s usually needed for mania (≥ 1200 mg/day). It’s a less potent inducer than carbamazepine—about 50% less so—but this is no reassurance when it comes to the CYP3A4 interaction with the highest stakes: oral contraceptives.

More practical tips on how to use oxcarbazepine are in the table on page 2.

TCPR Verdict: Oxcarbazepine sits on a pile of flawed studies in bipolar disorder. We can’t say that it works, but we can’t rule it out. Avoid using it as the sole mood stabilizer, particularly in bipolar I disorder. It may have a role as an augmentation therapy in mania and mixed states, but even then it is third line. Oxcarbazepine has slightly fewer side effects and drug interactions than carbamazepine, but it’s not safer—hyponatremia is common and dangerous when taking oxcarbazepine.

Listen to the Podcast Episode


The Choice: Oxcarbazepine or Carbamazepine in Bipolar




 
General Psychiatry
KEYWORDS bipolar_disorder carbamazepine free_articles mania mood_stabilizers oxcarbazepine pharmacology psychopharm-myths psychopharmacology
    www.thecarlatreport.com
    Issue Date: March 9, 2020
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Bipolar II, TCPR, March 2020
    Oxcarbazepine: Close, but no Cigar
    Psychopharmacology in Bipolar II
    Lumateperone and lemborexant
    Optimal Antidepressant Doses in Major Depression
    Highlight From This Issue
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.